IceCure Medical Ltd. Ordinary Shares (ICCM) Dividend History

Company News

• IceCure (ICCM) Q1 2025 Earnings Call Transcript

  IceCure Medical reported stable Q1 2025 results, with revenue and gross margin slightly down year-over-year. The company submitted a post-market study plan to the FDA for its ProSense cryoablation system, a key step towards potential marketing authorization for early-stage breast cancer treatment in women aged 70 and older. IceCure is preparing for a U.S. commercial launch upon FDA approval and is also pursuing regulatory filings in Japan and Israel.

  The Motley Fool
• IceCure Announces Positive FDA Development: Understanding on Path Forward for Marketing Authorization of ProSense® Cryoablation in Women 70+ with Early-Stage Breast Cancer

  IceCure Medical announced a positive meeting with the FDA regarding the marketing authorization of its ProSense® cryoablation system for treating early-stage breast cancer in women aged 70 and over. The FDA requested a post-market study, which IceCure plans to conduct, and upon approval of the study plan, the FDA is expected to grant final marketing authorization.

  Benzinga
• IceCure's (ICCM) ProSense Breast Cancer Study Meets Endpoint - Zacks Investment Research

  IceCure Medical's ProSense cryoablation system has shown promising results in treating breast cancer, with a 100% complete ablation rate and no complications in an outpatient setting. The study supports the use of cryoablation as a minimally invasive, outpatient treatment option for breast cancer patients.

  Zacks Investment Research

  Featured Companies: DVA DXCM UHS
• IceCure Medical Regains Compliance with Nasdaq Minimum Closing Bid Price Rule

  CAESAREA, Israel, Jan. 12, 2024 (GLOBE NEWSWIRE) -- IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure” or the “Company”), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that it has received a written notice from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5550(a)(2), which requires listed securities, including the Company's ordinary shares, to maintain a minimum bid price of $1.00 per share.

  GlobeNewswire Inc.
• 3 Tips for Identifying Penny Stocks With High Potential

  Use these tips for finding penny stocks to buy in 2022 The post 3 Tips for Identifying Penny Stocks With High Potential appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

  PennyStocks